Page last updated: 2024-08-24

nelfinavir and mefloquine

nelfinavir has been researched along with mefloquine in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80

Authors

Authors	Studies
Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chellappan, DK; Collet, TA; Dighe, SN; Dua, K; Ekwudu, O; Katavic, PL	1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF	1
Burger, DM; den Hartigh, J; Hoetelmans, RM; Hugen, PW; Kroon, FP; Schippers, EF; Visser, LG	1

Reviews

3 review(s) available for nelfinavir and mefloquine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Recent update on anti-dengue drug discovery. European journal of medicinal chemistry, 2019, Aug-15, Volume: 176 Topics: Animals; Antiviral Agents; Biological Products; Cell Line, Tumor; Dengue Virus; Drug Discovery; Humans; Serine Proteinase Inhibitors; Viral Nonstructural Proteins; Virus Replication	2019
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European journal of medicinal chemistry, 2022, Jul-05, Volume: 237 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells	2022

Other Studies

2 other study(ies) available for nelfinavir and mefloquine

Article	Year
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching. Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21 Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity	2013
No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS (London, England), 2000, Dec-01, Volume: 14, Issue:17 Topics: Antimalarials; Antiretroviral Therapy, Highly Active; Drug Interactions; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Malaria; Mefloquine; Nelfinavir	2000

Article

Year

Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.

Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21

Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity

2013

No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.

AIDS (London, England), 2000, Dec-01, Volume: 14, Issue:17

Topics: Antimalarials; Antiretroviral Therapy, Highly Active; Drug Interactions; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Malaria; Mefloquine; Nelfinavir

2000